Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 5:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,105 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Skin and Skin-structure Infections Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

NCT04018599
View directory record Official record
Conditions
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study

NCT02933879
View directory record Official record
Conditions
Onychomycosis
Interventions
NVXT topical, Placebo (Vehicle) Topical
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Jul 21, 2026, 5:03 AM EDT
Recruiting Phase 2 Interventional

A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

NCT07244263
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Zasocitinib (Dose A), Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
15
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers

NCT00659646
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
gentamicin-collagen sponge and levofloxacin, Levofloxacin only
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Lakeland, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Jul 21, 2026, 5:03 AM EDT
Enrolling by invitation Not applicable Interventional

Advancing Health Information Exchange (HIE) During Inter-hospital Transfer (IHT) to Improve Patient Outcomes

NCT05443321
View directory record Official record
Conditions
Infections, Heart Failure, COPD Exacerbation, Asthma, Gastrointestinal Diseases, Cardiac Event, Arrythmia, Renal Failure, Renal Disease, Rheumatic Diseases, Urologic Diseases, Neurologic Disorder, Hematologic Diseases, Oncology Problem, Shock, Critical Illness
Interventions
Health Information Exchange (HIE) platform
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 2 Interventional Results available

Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults

NCT01685372
View directory record Official record
Conditions
Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder, Human Immunodeficiency Virus (HIV), Bone Marrow Transplant (BMT), Dialysis
Interventions
Fluzone High Dose, Fluzone
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 2 Interventional

Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)

NCT00869336
View directory record Official record
Conditions
Tinea Pedis
Interventions
Luliconazole Cream 1% - 2 wks, Placebo Comparator -2 wks, Luliconazole Cream 1% - 4 wks, Placebo Comparator - 4 wks
Drug
Lead sponsor
Tinea Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
4
States / cities
Fridley, Minnesota • Portland, Oregon • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2011 · Synced Jul 21, 2026, 5:03 AM EDT
Not listed Phase 4 Interventional

PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age With Scabies

NCT05310734
View directory record Official record
Conditions
Scabies
Interventions
Spinosad Topical
Drug
Lead sponsor
Cipher Pharmaceuticals Inc.
Industry
Eligibility
1 Month to 4 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Miami, Florida • Lafayette, Louisiana • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Jul 21, 2026, 5:03 AM EDT
Completed No phase listed Observational

Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study

NCT06297187
View directory record Official record
Conditions
Vulvar Intraepithelial Neoplasia, Condylomata Acuminata
Interventions
CUSA (Cavitronic Ultrasonic Surgical Aspirator)
Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
56 participants
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 21, 2026, 5:03 AM EDT
Recruiting No phase listed Observational

Diagnosis and Treatment of Leishmania Infections

NCT00344188
View directory record Official record
Conditions
Leishmaniasis, Skin Diseases, Parasitic, Euglenozoa Infections, Parasitic Diseases
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 100 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 21, 2026, 5:03 AM EDT
Terminated No phase listed Observational

How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes

NCT03370861
View directory record Official record
Conditions
Autoimmunity, Melanoma, Merkel Cell Carcinoma, Squamous Cell Carcinoma of the Skin, Basal Cell Carcinoma, Skin Cancer
Interventions
Immunotherapy
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 1 Interventional

Rituximab for Anti-cytokine Autoantibody-Associated Diseases

NCT01842386
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis
Interventions
Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 21, 2026, 5:03 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

NCT05139602
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Lutikizumab, Placebo
Biological · Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 21, 2026, 5:03 AM EDT
Completed No phase listed Observational

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

NCT02910557
View directory record Official record
Conditions
Melanoma, Herpetic Infection
Interventions
Not listed
Lead sponsor
Amgen
Industry
Eligibility
Not listed
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
9
States / cities
Coral Springs, Florida • Baltimore, Maryland • Jefferson City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

NCT01290341
View directory record Official record
Conditions
Tinea Pedis
Interventions
NAFT-600 (naftin 2 % gel), Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
23
States / cities
Tucson, Arizona • Encino, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2013 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluate the Efficacy of a Silk-Like Fabric for the Prevention of Pressure Sores in a Long Term Care Setting

NCT01403272
View directory record Official record
Conditions
Pressure Ulcers
Interventions
DermaTherapy® Linen and underpads.
Device
Lead sponsor
Precision Fabrics Group, Inc.
Other
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2011 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 3 Interventional

Herpetic Eye Disease Study (HEDS) II

NCT00000139
View directory record Official record
Conditions
Keratitis, Herpetic, Ocular Herpes Simplex, Herpes Simplex
Interventions
Stress, Acyclovir
Behavioral · Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
8
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2010 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

NCT00116844
View directory record Official record
Conditions
Infections, Herpesviridae
Interventions
Valaciclovir, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
17
States / cities
Carmichael, California • Davis, California • Riverside, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2018 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 3 Interventional Results available

Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia

NCT00855309
View directory record Official record
Conditions
Herpes Simplex
Interventions
acyclovir sodium
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Jul 21, 2026, 5:03 AM EDT
Terminated No phase listed Observational

Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

NCT00957736
View directory record Official record
Conditions
Cancer
Interventions
polymorphism analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Not applicable Interventional Results available

Evaluating the Effect of a Written Action Plan on Comfort and Understanding of Hidradenitis Suppurativa

NCT04600375
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Verbal consultation, Written Action Plan
Behavioral
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 89 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis

NCT00361881
View directory record Official record
Conditions
Herpes Labialis
Interventions
ME-609, acyclovir in ME-609 vehicle, Vehicle
Drug
Lead sponsor
Medivir
Industry
Eligibility
18 Years and older
Enrollment
1,443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 17, 2008 · Synced Jul 21, 2026, 5:03 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections

NCT00711802
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
Daptomycin, Standard of Care (SOC)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
1 Year to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
22
States / cities
Birmingham, Alabama • Oakland, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jul 21, 2026, 5:03 AM EDT
Terminated Phase 2 Interventional Results available

Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).

NCT05997277
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Deucravacitinib, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 21, 2026, 5:03 AM EDT